Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study
- 235 Downloads
Background Guidelines recommend patients diagnosed with transient ischaemic attack (TIA) or ischaemic stroke receive antihypertensive, antithrombotic and lipid lowering medicines. Reassessment of the need for medicines associated with an increased risk of stroke is also recommended. Objective To determine changes in the use of medicines recommended for secondary stroke prevention, medicines commonly used for treating stroke-related complications and medicines not recommended for use after ischaemic stroke, and to determine patient characteristics associated with use of all three stroke prevention medicines after TIA or ischaemic stroke. Setting Administrative health claims data from the Australian Government Department of Veterans’ Affairs. Method This retrospective study included patients with a first-ever hospitalisation for TIA or ischaemic stroke in 2009 and alive at 4 months after discharge. Changes to medicines dispensed in the 4 months before and after hospitalisation were compared using McNemar’s test. Log binomial regression analysis was used to determine patient characteristics associated with use of all three secondary stroke prevention medicines after hospitalisation for TIA or ischaemic stroke. Main outcome measure Prevalence of medicine use after hospitalisation. Results 1541 patients (853 TIA, 688 ischaemic stroke) were included, with a median age of 85 years. High use of antihypertensive (82 % TIA, 86 % ischaemic stroke) and antithrombotic (84 % TIA, 90 % ischaemic stroke) medicines was observed postdischarge, with 58 % of TIA and 73 % of ischaemic stroke patients receiving lipid lowering therapy. Half of the population (47 % TIA, 61 % ischaemic stroke) were dispensed all three classes of medicines recommended for secondary stroke prevention after discharge. Ischaemic stroke patients, younger patients, patients with more comorbid conditions and those discharged home were more likely to receive all three recommended medicine classes. Antibiotics (45 % TIA, 46 % ischaemic stroke), paracetamol (44 % TIA, 47 % ischaemic stroke), antidepressants (26 % TIA, 31 % ischaemic stroke) and laxatives (24 % TIA, 32 % ischaemic stroke) were commonly used after discharge. Increased use of sedatives and reduced use of non-steroidal anti-inflammatories was also observed after discharge. Conclusion Changes to pharmacotherapy after TIA or ischaemic stroke were consistent with treatment for stroke risk factors and common stroke-related complications. Use of secondary stroke prevention medicines may be further improved among TIA patients.
KeywordsAustralia Drug utilisation Older people Stroke Transient ischaemic attack
The authors thank the Australian Government Department of Veterans’ Affairs (DVA) for providing data to conduct this research. This manuscript was reviewed by DVA prior to submission.
J Sluggett was supported by an Australian Postgraduate Award and University of South Australia scholarship.
Conflicts of interest
The authors have no conflicts of interest to declare.
- 2.MacKay J, Mensah GA, Mendis S, Greenlund K. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004. ISBN: 9789241562768.Google Scholar
- 5.Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Cardiovascular disease series. Cat. no. CVD 53. Canberra: AIHW: 2011. ISBN: 978-1-74249-130-1.Google Scholar
- 6.National Stroke Foundation. Clinical guidelines for stroke management 2010. Melbourne, Australia: 2010. ISBN: 978-0-9805933-3-4.Google Scholar
- 7.The European stroke organisation. Guidelines for management of ischaemic stroke and transient ischaemic attack; 2008. (cited 26 Sept 2014). http://www.congrex-switzerland.com/fileadmin/files/2013/eso-stroke/pdf/ESO08_Guidelines_Original_english.pdf.
- 8.Intercollegiate Stroke Working Party. National clinical guideline for stroke. 4th ed. London: Royal College of Physicians; 2012. ISBN: 978-1-86016-492-7.Google Scholar
- 13.National stroke foundation. National stroke audit—acute services clinical audit report 2013. (cited 10 Mar 2014). http://strokefoundation.com.au/site/media/NSF687.ClinicalServicesAudit2013.Final_.pdf. ISBN: 987-0-9872830-7-8.
- 17.Australian Government Department of Veterans’ Affairs. Treatment population statistics, quarterly report, Dec 2010. (cited 15 Dec 2013). http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopDec2010.pdf.
- 18.World Health Organisation Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. (cited 21 Dec 2011). http://www.whocc.no/atc_ddd_index/.
- 19.Australian Government Department of Health. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2014. (cited 26 Sept 2014). http://www.pbs.gov.au/publication/schedule/2014/09/2014-09-01-general-schedule.pdf.
- 20.National Centre for Classification in Health. International statistical classification of diseases and related health problems, Tenth Revision, Australian Modification (ICD-10-AM). National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney: Sydney; 2004.Google Scholar
- 25.National Stroke Foundation. National stroke audit acute services—clinical audit report 2009. (cited 10 Nov 2011]. http://www.strokefoundation.com.au/index2.php?option=com_docman&task=doc_view&gid=268&Itemid=39.
- 28.National Stroke Foundation. Clinical Guidelines for Acute Stroke Management. Melbourne, Australia: 2007. (cited 26 Sept 2014). http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp109.pdf.
- 40.Australian Institute of Health and Welfare. Health care usage and costs. A comparison of veterans and war widows and widowers within the rest of the community. AIHW Cat. no. PHE 42. Canberra: AIHW 2002. ISBN: 978-1-75024-234-6.Google Scholar